Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment
Latent reservoir persistence remains a major obstacle for curing human immunodeficiency virus type 1 (HIV-1) infection. Thus, strategies for the elimination of latent HIV-1 are urgently needed. As a bromodomain and extra-terminal (BET) inhibitor, BMS-986158 has been used in clinical trials for advan...
Saved in:
Main Authors: | Xu-Sheng Huang (Author), Ren-Rong Tian (Author), Meng-Di Ma (Author), Rong-Hua Luo (Author), Liu-Meng Yang (Author), Guang-Hui Peng (Author), Mi Zhang (Author), Xing-Qi Dong (Author), Yong-Tang Zheng (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Roles of Bromodomain Extra Terminal Proteins in Metabolic Signaling and Diseases
by: Dayu Wu, et al.
Published: (2022) -
Bromodomain and Extra-Terminal Protein Inhibitors: Biologic Insights and Therapeutic Potential in Pediatric Brain Tumors
by: Andrew Groves, et al.
Published: (2022) -
Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials
by: Yanli Sun, et al.
Published: (2021) -
Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
by: Gerhard Hamilton, et al.
Published: (2023) -
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
by: Chiara Tarantelli, et al.
Published: (2021)